Paclitaxel + Eribulin + Gemcitabine
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Breast Cancer
Conditions
Metastatic Breast Cancer
Trial Timeline
Dec 19, 2014 → Jun 17, 2019
NCT ID
NCT02263495About Paclitaxel + Eribulin + Gemcitabine
Paclitaxel + Eribulin + Gemcitabine is a phase 2 stage product being developed by Eisai for Metastatic Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02263495. Target conditions include Metastatic Breast Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Breast Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02263495 | Phase 2 | Completed |
Competing Products
20 competing products in Metastatic Breast Cancer